Metabolic effects of phosphodiesterase III inhibitors: another reason to promote their use?

Phosphodiesterase III inhibitors combine positive inotropic and vasodilator properties. These inhibitors are therefore frequently used to treat low cardiac output and/or severe left heart failure associated with cardiac surgery. Their effects on energy metabolism and visceral organ function are not...

Descripción completa

Detalles Bibliográficos
Autores principales: Simkova, Vladislava, Radermacher, Peter, Barth, Eberhard
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2007
Materias:
Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2206415/
https://www.ncbi.nlm.nih.gov/pubmed/17572916
http://dx.doi.org/10.1186/cc5924
_version_ 1782148466514853888
author Simkova, Vladislava
Radermacher, Peter
Barth, Eberhard
author_facet Simkova, Vladislava
Radermacher, Peter
Barth, Eberhard
author_sort Simkova, Vladislava
collection PubMed
description Phosphodiesterase III inhibitors combine positive inotropic and vasodilator properties. These inhibitors are therefore frequently used to treat low cardiac output and/or severe left heart failure associated with cardiac surgery. Their effects on energy metabolism and visceral organ function are not well studied, however, particularly in comparison with their 'competitors' in daily practice (that is, catecholamines).
format Text
id pubmed-2206415
institution National Center for Biotechnology Information
language English
publishDate 2007
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-22064152008-01-19 Metabolic effects of phosphodiesterase III inhibitors: another reason to promote their use? Simkova, Vladislava Radermacher, Peter Barth, Eberhard Crit Care Commentary Phosphodiesterase III inhibitors combine positive inotropic and vasodilator properties. These inhibitors are therefore frequently used to treat low cardiac output and/or severe left heart failure associated with cardiac surgery. Their effects on energy metabolism and visceral organ function are not well studied, however, particularly in comparison with their 'competitors' in daily practice (that is, catecholamines). BioMed Central 2007 2007-06-11 /pmc/articles/PMC2206415/ /pubmed/17572916 http://dx.doi.org/10.1186/cc5924 Text en Copyright © 2007 BioMed Central Ltd
spellingShingle Commentary
Simkova, Vladislava
Radermacher, Peter
Barth, Eberhard
Metabolic effects of phosphodiesterase III inhibitors: another reason to promote their use?
title Metabolic effects of phosphodiesterase III inhibitors: another reason to promote their use?
title_full Metabolic effects of phosphodiesterase III inhibitors: another reason to promote their use?
title_fullStr Metabolic effects of phosphodiesterase III inhibitors: another reason to promote their use?
title_full_unstemmed Metabolic effects of phosphodiesterase III inhibitors: another reason to promote their use?
title_short Metabolic effects of phosphodiesterase III inhibitors: another reason to promote their use?
title_sort metabolic effects of phosphodiesterase iii inhibitors: another reason to promote their use?
topic Commentary
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2206415/
https://www.ncbi.nlm.nih.gov/pubmed/17572916
http://dx.doi.org/10.1186/cc5924
work_keys_str_mv AT simkovavladislava metaboliceffectsofphosphodiesteraseiiiinhibitorsanotherreasontopromotetheiruse
AT radermacherpeter metaboliceffectsofphosphodiesteraseiiiinhibitorsanotherreasontopromotetheiruse
AT bartheberhard metaboliceffectsofphosphodiesteraseiiiinhibitorsanotherreasontopromotetheiruse

Ejemplares similares